Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O60479
UPID:
DLX3_HUMAN
Alternative names:
-
Alternative UPACC:
O60479; B3KQL6
Background:
Homeobox protein DLX-3 plays a pivotal role in the development of the ventral forebrain, contributing to craniofacial patterning and morphogenesis. This protein's regulatory functions are crucial for proper facial development.
Therapeutic significance:
Homeobox protein DLX-3 is implicated in Trichodentoosseous syndrome and Amelogenesis imperfecta 4, diseases affecting dental and skeletal development. Targeting DLX-3 could lead to innovative treatments for these genetic disorders.